ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Missing protein explains link between obesity, diabetes

Single tick bite can pack double pathogen punch

Fish oil use associated with brain volume preservation

The Brain Boosting and Fatigue Fighting B-12

Genetic basis for distinct type of autism uncovered

Higher vitamin D levels associated with better cancer prognosis

Genetic study suggests causal link between vitamin D deficiency and hypertension

Unsuspected aspect of immune regulation revealed: Role of B cells

Explaining 'Healthy' Obesity

IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders

 
Print Page
Email Article

Patient Survey Results for FDA Drug Development Meeting for ME and CFS, April 25-26, 2013

  [ Not Yet Rated ]   [ Post a Comment ]
By Lily Chu et al. • www.ProHealth.com • May 19, 2013


By Lily Chu, Leonard Jason, Madison Sunnquist, Suzanna So

Preliminary Results – April 2013 FDA Workshop Survey 

Demographics: 

85% of our subjects were female and almost all subjects were Caucasian.  The average age was 51 and the average duration of illness was 18 years. For 50% of our respondents, this survey is the only way they are participating in this workshop. 

Symptoms:

The 5 most significant symptoms were fatigue, post-exertional malaise, pain, sleep, and cognitive problems. Symptoms that haven’t been studied as much such as multiple chemical sensitivities, gastrointestinal symptoms, and orthostatic intolerance were also deemed to be significant by over 50% of our subjects.. 

99% felt that their illness was not improving over time, citing worsening of existing symptoms and appearance of new symptoms.

Out of five objective tests we asked about, 66% had at least one abnormal result. For natural killer cell activity, for example, 70% noted an abnormal result. Tests like these could be used as study inclusion criteria, as outcome measures, and as a way to select subgroups for analysis. We believe that studying subgroups may help yield more effective treatments given the heterogenous nature of CFS.

Impact on Daily Life:

Using a standardized measure of physical functioning, we found our respondents to be more disabled than 95% of the general US population. Only 13% were employed, with almost all citing ME and or CFS as the reason for why they could not work. For even basic personal care, 89% needed assistance or had to change their pre-illness routine. On their worst days, 60% were bedridden. On their best days, 75% could only do some light housework or less. 

Five example tests to consider in CFS:

Test Number who got tested Normal Abnormal Not sure if tested/result
NK cell activity 172 7% 70% 23%
Repeated CPET 173 31 63 5
Brain Imaging 216 49 46 6
Neuropsych test 172 31 53 16
Tilt Table 132 16 80 5

For each test, between 40%-60% of respondents answering the question had never had the test before due partly to cost, insurance coverage, and physician resistance to ordering a test; they're excluded from the above table. Results above are those who had the test, think they might have had it but are not sure, or did not remember the result but had the test.

Perspectives on Current Treatment:

75% of people felt current treatments were not helpful or only slightly helpful but not enough to improve their day-to-day function. Patients  repeatedly wrote about the need for disease-modifying treatments and not only for treatments that helped control symptoms.

We asked about how well currently recommended treatments worked for the illness overall and for three common symptoms: sleep, pain, and cognitive problems. 

These treatments were cited as helpful by more than 50% of subjects:

  • for the overall illness - balancing rest with activity, restricting or modifying physical/ mental activities
  • for sleep – CPAP, over-the-counter medicines, zolpidem, eszoplicone, TCAs, trazodone, benzodiazepines
  • for pain – short/ long-acting opioids, flexeril, ibuprofen

Some alternative/ complementary/ non-drug treatments also made the cut. Helpful prescription drugs cited in patient comments included gamma-hyroxybutyric acid for sleep, lisdexamfetamine for thinking, tizanadine/ baclofen for pain, and midodrine/ florinef/ beta-blockers for orthostatic intolerance.  In contrast, exercise programs, administered by a professional and part of the current standard of care, were noted by 62% as worsening their health. 

The main reasons cited for stopping a medicine were side effects followed by decrease in effectiveness over time, especially with sleep medications. For effective non-drug treatments, cost and insurance coverage were major reasons for discontinuation. Respondents were also concerned about being more sensitive to drugs and the dependency potential of some medications.

Limitations:

The overwhelming majority of respondents to our survey self-identified as Caucasian. This is likely a result of adequate access to care to obtain an accurate diagnosis, Internet access, and membership in support groups rather than an accurate reflection of the epidemiology of ME or CFS. In fact, multiple community-based studies suggest a higher prevalence and more severe morbidity in minority populations. 

We did ask about antibiotics, antivirals, and immunomodulators but 1) answers were rather mixed (side effects, not enough time on medicine due to physician/ cost, etc.) 2) sample sizes were too small to come to concrete conclusions. Also, to date, no blockbuster drug has been noted in open patient comments to be very successful by more than a handful of respondents. In addition given the relatively short length/ nature of the survey, we weren't able to subgroup respondents and ask how they did on various treatments, which I think is key to finding effective treatments.

For more information, contact Lily Chu (lilyxchu@gmail.com)




Join the Discussion Post a Comment 




[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Your Next Order

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Undenatured Type II Collagen - Chicken Soup for Your Joints Undenatured Type II Collagen - Chicken Soup for Your Joints
Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH
Ubiquinol - A More Advanced Form of the Energy Producing Nutrient CoQ-10 Ubiquinol - A More Advanced Form of the Energy Producing Nutrient CoQ-10
Sleep Like a Baby in Nature's Cradle Sleep Like a Baby in Nature's Cradle
Red: The Color of Energy, Health, and B-12 Red: The Color of Energy, Health, and B-12

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing